RBC Capital Reiterates Outperform on Pyxis Oncology, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on Pyxis Oncology (NASDAQ:PYXS) and maintained a $7 price target.
March 22, 2024 | 2:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating and a $7 price target on Pyxis Oncology.
The reiteration of an Outperform rating and maintenance of a $7 price target by a reputable analyst like Leonid Timashev from RBC Capital could instill confidence among investors and potentially lead to a positive short-term impact on PYXS's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100